Tag: Human Papillomavirus (HPV)
Protection Similar With Single, Multiple HPV Vaccine Doses
Infection with HPV 6, 11, 16, 18 less prevalent among women receiving one, two, three doses of HPV vaccine
Extending HPV Vaccination to Age 45 Provides Small Additional Benefit
Vaccinating women and men to age 45 years predicted to have high costs per QALY gained
Studies Confirm Safety of 9-Valent HPV Vaccination
Studies based on searching Vaccine Adverse Event Reporting System, six Vaccine Safety Datalink sites
Mailing HPV Kits to Underscreened Women Can Up Screening
No significant difference found in detection of CIN2+ or treatment with intervention versus usual care
HPV DNA Identified in Oral Cavity of 6.2 Percent of Teen Girls
Oral HPV detection decreased with number of years since first engaging in sexual activities
Incidence of HPV-Positive Head and Neck Cancer Up in the U.S.
From 2013 to 2014, incidence of HPV-positive oropharyngeal cancers was 4.62 per 100,000 persons
Men Less Knowledgeable About HPV, HPV Vaccination
Most men and women did not know anal, penile, and oral cancers are caused by HPV
Room for Improvement Found in HPV Vaccine Delivery Practices
Physicians not strongly recommending vaccine, not using presumptive style linked to refusal or deferral
Herd Protection Against Oral HPV Infections Seen Among Men
Vaccine-type oral HPV prevalence decreased from 2009-2010 to 2015-2016 among unvaccinated men
Most HPV-Linked Cancers Due to Types Targeted by 9vHPV Vaccine
In 2012 to 2016, 92 percent of cancers attributable to HPV due to HPV types targeted by 9vHPV vaccine
